Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the body attacks its own cells. Autoimmune diseases are a major cause of immune-mediated diseases, and are commonly referred to as Autoimmune and Inflammatory Diseases (AIID).
Women tend to be affected more often by autoimmune disorders; nearly 79% of autoimmune disease patients in the USA are women. Also they tend to appear during or shortly after puberty. It is not known why this is the case, although hormone levels have been shown to affect the severity of some autoimmune diseases such as multiple sclerosis.[1] Other causes may include the presence of fetal cells in the maternal bloodstream. [2]
In both autoimmune diseases and inflammation, the condition is triggered by aberrant reactions of the human immune system. In autoimmunity, the patient’s immune system is activated against the body's own proteins. In inflammatory diseases, it is the overreaction of the immune system, and its subsequent downstream signaling (TNF, INF, etc), which causes problems.
A substantial proportion of the population suffers from immune diseases, which are often chronic, debilitating, and life-threatening. There are more than eighty illnesses caused by autoimmunity and about 75 percent of those affected are women. It has been estimated that autoimmune diseases are among the ten leading causes of death among women in all age groups up to 65 years.[28]
Currently, a considerable amount of research is being conducted in this therapeutic segment. According to a report from Frost & Sullivan, the total alliance payouts in the autoimmune/inflammation segment from 1997 to 2002 totaled $489.8 million, where Eli Lilly, Suntory, Procter & Gamble, Encysive, and Novartis together account for 98.6 percent of alliance payouts.[29]
The incidence of these diseases is expected to rise because of a number of factors, including increasing environmental pollution, allowing for even more opportunity in this market. Advances in biotechnology are also enriching research work in this area. Secondary to cancer and infectious diseases, autoimmune disorder is the therapeutic category with the most number of biotech drugs under development.
Treatment therapies which have failed to cure diseases such as cancer, immunological and inflammatory disorders, auto-immune diseases, and infectious diseases have driven the need for creation and development of innovative and meaningful biotherapeutics to address important unmet medical needs in these areas. Considerable research is being conducted worldwide to develop more effective drugs for asthma, allergies, inflammation and other diseases that affect the human immune system, but there are certain medical needs in these areas which demand the development of highly efficient and safe therapeutic agents for optimal use in man. To address all of these needs for therapeutics, recent advances in monoclonal antibody development may offer potential targets for effective immunotherapy.
^ Hyland KV, Engman DM (2006). "Further thoughts on where we stand on the autoimmunity hypothesis of Chagas disease". Trends Parasitol.22 (3): 101–2; author reply 103. doi:10.1016/j.pt.2006.01.001. PMID 16446117.
^ Agustí A, MacNee W, Donaldson K, Cosio M. (2003). "Hypothesis: does COPD have an autoimmune component?". Thorax58 (10): 832–834. doi:10.1136/thorax.58.10.832. PMID 14514931.
^ Lee SH, Goswami S, Grudo A, et al (2007). "Antielastin autoimmunity in tobacco smoking-induced emphysema". Nat. Med.13 (5): 567–9. doi:10.1038/nm1583. PMID 17450149.
^ Gleicher N, el-Roeiy A, Confino E, Friberg J (1987). "Is endometriosis an autoimmune disease?". Obstetrics and gynecology70 (1): 115–22. PMID 3110710.
^ Kárpáti F, Dénes L, Büttner K (1975). "[Interstitial cystitis=autoimmune cyatitis? Interstitial as a participating disease in lupus erythematosus]" (in German). Zeitschrift für Urologie und Nephrologie68 (9): 633–9. PMID 1227191.
^ Carlander, B., Eliaou J.F., Billiard M. (1993). "Autoimmune hypothesis in narcolepsy.". Neurophysiol. Clin.23: 15. doi:10.1016/S0987-7053(05)80279-5.
^ Maddison P (2006). "Neuromyotonia". Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology117 (10): 2118–27. doi:10.1016/j.clinph.2006.03.008. PMID 16843723.
^ Eaton WW, Byrne M, Ewald H, et al (2006). "Association of schizophrenia and autoimmune diseases: linkage of Danish national registers". The American journal of psychiatry163 (3): 521–8. doi:10.1176/appi.ajp.163.3.521. PMID 16513876.
^ Jones AL, Mowry BJ, Pender MP, Greer JM (2005). "Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?". Immunol. Cell Biol.83 (1): 9–17. doi:10.1111/j.1440-1711.2005.01305.x. PMID 15661036.
^ Strous RD, Shoenfeld Y (2006). "Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited". J. Autoimmun.27 (2): 71–80. doi:10.1016/j.jaut.2006.07.006. PMID 16997531.